Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
13.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 28, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech's Earnings: A Preview
November 27, 2023
Via
Benzinga
Earnings Scheduled For November 28, 2023
November 28, 2023
Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion.
Via
Benzinga
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
November 21, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 14, 2023
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
November 10, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
Alvotech
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
October 20, 2023
Via
Benzinga
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
October 12, 2023
From
Alvotech
Via
GlobeNewswire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Kashiv Biosciences LLC
Via
Business Wire
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 03, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
September 25, 2023
From
Alvotech
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023
September 21, 2023
Via
Benzinga
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Changes to the Leadership Team
September 05, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For August 30, 2023
August 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter.
Via
Benzinga
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
August 29, 2023
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure
From
Alvotech
Via
GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 22, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and FMC and Encourages Investors to Contact the Firm
August 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
July 31, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.